Shaanxi Kanghui Pharm Co Ltd Total Assets
Shaanxi Kanghui Pharm Co Ltd total assets. Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) holds total assets worth CN¥1.71 Billion CNY (≈ $249.51 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 603139 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Shaanxi Kanghui Pharm Co Ltd (2012–2025)
Total assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025. This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See Shaanxi Kanghui Pharm Co Ltd share price for real-time trading data and today's change.
Shaanxi Kanghui Pharm Co Ltd - Asset Composition Analysis
Shaanxi Kanghui Pharm Co Ltd Total Assets Breakdown (December 2025)
Shaanxi Kanghui Pharm Co Ltd total assets breakdown as of December 2025. Shaanxi Kanghui Pharm Co Ltd's total assets of CN¥1.71 Billion consist of 32.5% current assets and 67.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.9% |
| Accounts Receivable | CN¥226.74 Million | 12.5% |
| Inventory | CN¥163.14 Million | 9.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.29 Million | 4.8% |
| Goodwill | CN¥7.49 Million | 0.4% |
Asset Composition Trend (2012–2025)
This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Shaanxi Kanghui Pharm Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shaanxi Kanghui Pharm Co Ltd's current assets represent 32.5% of total assets in 2025, a decrease from 73.6% in 2012.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, down from 14.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 12.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 12.5% of total assets.
Shaanxi Kanghui Pharm Co Ltd Competitors by Total Assets
Key competitors of Shaanxi Kanghui Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Shaanxi Kanghui Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 0.95 | 5.59 |
| Quick Ratio | 0.41 | 0.67 | 4.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-329.06 Million | CN¥-32.98 Million | CN¥666.05 Million |
Shaanxi Kanghui Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shaanxi Kanghui Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.46 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CN¥1.81 Billion |
| Market Capitalization | $426.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shaanxi Kanghui Pharm Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shaanxi Kanghui Pharm Co Ltd's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shaanxi Kanghui Pharm Co Ltd (2012–2025)
The table below shows the annual total assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.81 Billion ≈ $265.51 Million |
-3.89% |
| 2024-12-31 | CN¥1.89 Billion ≈ $276.25 Million |
-7.99% |
| 2023-12-31 | CN¥2.05 Billion ≈ $300.23 Million |
+12.63% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.57 Million |
-2.07% |
| 2021-12-31 | CN¥1.86 Billion ≈ $272.21 Million |
+41.87% |
| 2020-12-31 | CN¥1.31 Billion ≈ $191.87 Million |
+15.97% |
| 2019-12-31 | CN¥1.13 Billion ≈ $165.45 Million |
+1.85% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.46 Million |
+7.60% |
| 2017-12-31 | CN¥1.03 Billion ≈ $150.99 Million |
+57.54% |
| 2016-12-31 | CN¥654.97 Million ≈ $95.84 Million |
+13.24% |
| 2015-12-31 | CN¥578.40 Million ≈ $84.64 Million |
+13.94% |
| 2014-12-31 | CN¥507.65 Million ≈ $74.28 Million |
+12.81% |
| 2013-12-31 | CN¥450.00 Million ≈ $65.85 Million |
+42.52% |
| 2012-12-31 | CN¥315.74 Million ≈ $46.20 Million |
-- |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more